☰

Keith L. Ligon - Publications

Affiliations: 
Pathology Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States 
Tree Info Grants Similar researchers PubMed Report error

243 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Finotto L, Cole B, Giese W, Baumann E, Claeys A, Vanmechelen M, Decraene B, Derweduwe M, Dubroja Lakic N, Shankar G, Nagathihalli Kantharaju M, Albrecht JP, Geudens I, Stanchi F, Ligon KL, et al. Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma. Embo Molecular Medicine. e18144. PMID 37791581 DOI: 10.15252/emmm.202318144  0.334
2023 Aquilanti E, Kageler L, Watson J, Baird DM, Jones RE, Hodges M, Szegletes ZM, Doench JG, Strathdee CA, McFaline Figueroa JR, Ligon K, Beck M, Wen PY, Meyerson M. Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume. Neuro-Oncology. PMID 36694348 DOI: 10.1093/neuonc/noad024  0.311
2020 Giannikou K, Zhu Z, Kim J, Winden KD, Tyburczy ME, Marron D, Parker JS, Hebert Z, Bongaarts A, Taing L, Long HW, Pisano WV, Alexandrescu S, Godlewski B, Nellist M, ... ... Ligon KL, et al. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 33051600 DOI: 10.1038/s41379-020-00659-9  0.317
2020 Alexandrescu S, Meredith DM, Lidov HG, Alaggio R, Novello M, Ligon KL, Vargas SO. Loss of H3K27me3 and nuclear expression of TLE1 in primary intracranial sarcoma, DICER1-mutant. Histopathology. PMID 32692439 DOI: 10.1111/His.14217  0.372
2020 Torre M, Vasudevaraja V, Serrano J, DeLorenzo M, Malinowski S, Blandin AF, Pages M, Ligon AH, Dong F, Meredith DM, Nasrallah MP, Horbinski C, Dahiya S, Ligon KL, Santi M, et al. Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathologica Communications. 8: 107. PMID 32665022 DOI: 10.1186/S40478-020-00980-Z  0.364
2020 Gojo J, Englinger B, Jiang L, Hübner JM, Shaw ML, Hack OA, Madlener S, Kirchhofer D, Liu I, Pyrdol J, Hovestadt V, Mazzola E, Mathewson ND, Trissal M, Lötsch D, ... ... Ligon KL, et al. Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell. 38: 44-59.e9. PMID 32663469 DOI: 10.1016/J.Ccell.2020.06.004  0.353
2020 Mineo M, Lyons SM, Zdioruk M, von Spreckelsen N, Ferrer-Luna R, Ito H, Alayo QA, Kharel P, Giantini Larsen A, Fan WY, Auduong S, Grauwet K, Passaro C, Khalsa JK, Shah K, ... ... Ligon KL, et al. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Molecular Cell. PMID 32504554 DOI: 10.1016/J.Molcel.2020.05.015  0.308
2020 Rahman R, Trippa L, Alden S, Fell G, Abbasi T, Mundkur Y, Singh NK, Talawdekar A, Husain Z, Vali S, Ligon KL, Wen PY, Alexander BM. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. International Journal of Radiation Oncology, Biology, Physics. PMID 32417407 DOI: 10.1016/J.Ijrobp.2020.05.010  0.343
2020 Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, ... ... Ligon KL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 580: 517-523. PMID 32322066 DOI: 10.1038/S41586-020-2209-9  0.386
2020 Mineo M, Lyons SM, Ferrer-Luna R, Ito H, Spreckelsen Nv, Alayo QA, Khalsa JK, Shah K, Ligon KL, Beroukhim R, Ivanov P, Anderson PJ, Nakashima H, Lawler SE, Chiocca EA. Abstract B46: The long noncoding RNA INCA1 is a novel regulator of PD-L1 expression in tumors Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-B46  0.32
2020 Bustoros MW, Cibulskis C, Dowdell T, Gavrilov S, Boehner C, Yesil J, Labkoff SE, Mehr S, Park J, Pistofidis RS, Manier S, Kim AS, Ligon KL, Lennon N, Adalsteinsson V, et al. Abstract A38: A novel clinical-grade liquid biopsy platform for multiple myeloma Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-A38  0.35
2020 Tseng Y, Keskula P, Deasy R, Hong A, Chatterji P, Vazquez F, Bass A, Hare BV, Sandak D, Ligon K, Boehm J. Abstract PR09: A systematic approach to create patient-derived models of rare tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-Pr09  0.397
2020 Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu B, Bohrson CL, Cortes-Ciriano I, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, ... ... Ligon KL, et al. Abstract 5705: Mechanisms and therapeutic implications of hypermutation in gliomas Cancer Research. 80: 5705-5705. DOI: 10.1158/1538-7445.Am2020-5705  0.392
2019 Green AL, DeSisto J, Flannery P, Lemma R, Knox A, Lemieux M, Sanford B, O'Rourke R, Ramkissoon S, Jones K, Perry J, Hui X, Moroze E, Balakrishnan I, O'Neill AF, ... ... Ligon K, et al. BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. PMID 31844250 DOI: 10.1038/S41388-019-1125-7  0.344
2019 Noonan JJ, Jarzabek M, Lincoln FA, Cavanagh BL, Pariag AR, Juric V, Young LS, Ligon KL, Jahns H, Zheleva D, Prehn JHM, Rehm M, Byrne AT, Murphy BM. Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers. 11. PMID 31842413 DOI: 10.3390/Cancers11122005  0.354
2019 Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, ... ... Ligon KL, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. PMID 31748746 DOI: 10.1038/S41586-019-1775-1  0.388
2019 Ahrendsen JT, Filbin MG, Chi SN, Manley PE, Wright KD, Bandopadhayay P, Clymer JR, Yeo KK, Kieran MW, Jones R, Lidov HG, Ligon KL, Alexandrescu S. Increasing value of autopsies in patients with brain tumors in the molecular era. Journal of Neuro-Oncology. PMID 31571114 DOI: 10.1007/S11060-019-03302-Z  0.38
2019 Wefers AK, Stichel D, Schrimpf D, Coras R, Pages M, Tauziède-Espariat A, Varlet P, Schwarz D, Söylemezoglu F, Pohl U, Pimentel J, Meyer J, Hewer E, Japp A, Joshi A, ... ... Ligon KL, et al. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathologica. PMID 31563982 DOI: 10.1007/S00401-019-02078-W  0.33
2019 Reitman ZJ, Paolella BR, Bergthold G, Pelton K, Becker S, Jones R, Sinai CE, Malkin H, Huang Y, Grimmet L, Herbert ZT, Sun Y, Weatherbee JL, Alberta JA, Daley JF, ... ... Ligon KL, et al. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nature Communications. 10: 3731. PMID 31427603 DOI: 10.1038/S41467-019-11493-2  0.416
2019 Li X, Martinez-Ledesma E, Zhang C, Gao F, Zheng S, Ding J, Wu S, Nguyen N, Clifford SC, Wen PY, Ligon KL, Yung WKA, Koul D. Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma. Cancer Research. PMID 31416846 DOI: 10.1158/0008-5472.Can-19-0325  0.319
2019 Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Science Translational Medicine. 11. PMID 31413142 DOI: 10.1126/Scitranslmed.Aaw5680  0.329
2019 Cagney DN, Miller MB, Dubuc A, Delalle I, Ligon AH, Chukwueke U, Al-Mefty O, Aizer A, Ligon K, Wen P. Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. Cureus. 11: e4726. PMID 31355086 DOI: 10.7759/Cureus.4726  0.36
2019 Hovestadt V, Smith KS, Bihannic L, Filbin MG, Shaw ML, Baumgartner A, DeWitt JC, Groves A, Mayr L, Weisman HR, Richman AR, Shore ME, Goumnerova L, Rosencrance C, Carter RA, ... ... Ligon KL, et al. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. PMID 31341285 DOI: 10.1038/S41586-019-1434-6  0.308
2019 Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, ... ... Ligon KL, et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. PMID 31327527 DOI: 10.1016/J.Cell.2019.06.024  0.376
2019 Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology. PMID 31276167 DOI: 10.1093/Neuonc/Noz119  0.391
2019 Bandopadhayay P, Piccioni F, O'Rourke R, Ho P, Gonzalez EM, Buchan G, Qian K, Gionet G, Girard E, Coxon M, Rees MG, Brenan L, Dubois F, Shapira O, Greenwald NF, ... ... Ligon KL, et al. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications. 10: 2400. PMID 31160565 DOI: 10.1038/S41467-019-10307-9  0.321
2019 Hong AL, Tseng YY, Wala JA, Kim WJ, Kynnap BD, Doshi MB, Kugener G, Sandoval GJ, Howard TP, Li J, Yang X, Tillgren M, Ghandi M, Sayeed A, Deasy R, ... ... Ligon KL, et al. Renal medullary carcinomas depend upon loss and are sensitive to proteasome inhibition. Elife. 8. PMID 30860482 DOI: 10.7554/Elife.44161  0.301
2019 Torre M, Meredith DM, Dubuc A, Solomon DA, Perry A, Vasudevaraja V, Serrano J, Snuderl M, Ligon KL, Alexandrescu S. Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. Journal of Neuropathology and Experimental Neurology. PMID 30816933 DOI: 10.1093/Jnen/Nlz011  0.4
2019 Miklja Z, Pasternak A, Stallard S, Nicolaides T, Kline-Nunnally C, Cole B, Beroukhim R, Bandopadhayay P, Chi S, Ramkissoon SH, Mullan B, Bruzek AK, Gauthier A, Garcia T, Atchison C, ... ... Ligon KL, et al. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro-Oncology. PMID 30805642 DOI: 10.1093/Neuonc/Noz022  0.374
2019 Bhaskaran V, Nowicki MO, Idriss M, Jimenez MA, Lugli G, Hayes JL, Mahmoud AB, Zane RE, Passaro C, Ligon KL, Haas-Kogan D, Bronisz A, Godlewski J, Lawler SE, Chiocca EA, et al. The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Nature Communications. 10: 442. PMID 30683859 DOI: 10.1038/S41467-019-08390-Z  0.302
2019 Reitman ZJ, Paolella B, Bergthold G, Pelton K, Jones R, Becker S, Sinai CE, Malkin H, Huang Y, Grimmett L, Herbert ZT, Sun Y, Weatherbee J, Alberta J, Daley J, ... ... Ligon KL, et al. Abstract 3647: Single cell RNA sequencing reveals mitogenic and progenitor gene programs inBRAF-rearranged pilocytic astrocytomas Cancer Research. 79: 3647-3647. DOI: 10.1158/1538-7445.Am2019-3647  0.43
2019 Bihannic L, Hovestadt V, Smith K, Filbin M, Shaw M, Baumgartner A, DeWitt J, Groves A, Mayr L, Weisman H, Richman A, Shore M, Goumnerova L, Rosencrance C, Carter R, ... ... Ligon K, et al. PDTM-32. RESOLVING MEDULLOBLASTOMA CELLULAR ARCHITECTURE BY SINGLE-CELL GENOMICS Neuro-Oncology. 21: vi194-vi194. DOI: 10.1093/Neuonc/Noz175.808  0.384
2019 Torre M, Ascha M, Harary M, Smith T, Aizer A, Ligon K, Reardon D, Barnholtz-Sloan J, Iorgulescu B. EPID-22. NEWLY-DIAGNOSED BRAIN TUMORS IN PEDIATRIC PATIENTS: EPIDEMIOLOGY IN THE UNITED STATES Neuro-Oncology. 21: vi79-vi79. DOI: 10.1093/Neuonc/Noz175.322  0.377
2019 Torre M, Ascha M, Harary M, Smith T, Aizer A, Ligon K, Reardon D, Barnholtz-Sloan J, Iorgulescu B. EPID-21. THE NATIONAL SPECTRUM OF NEWLY-DIAGNOSED BRAIN TUMORS IN ADULT PATIENTS VARIES SIGNIFICANTLY BY PATIENT DEMOGRAPHICS Neuro-Oncology. 21: vi79-vi79. DOI: 10.1093/Neuonc/Noz175.321  0.38
2019 Touat M, Li Y, Boynton A, Spurr L, Iorgulescu B, Birzu C, Pal S, Ferrer-Luna R, Geduldig J, Bellamy C, Younan N, Baldini C, Verreault M, Guillerm E, Ammari S, ... ... Ligon K, et al. DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS Neuro-Oncology. 21: vi73-vi73. DOI: 10.1093/Neuonc/Noz175.296  0.383
2019 Touat M, Li Y, Boynton A, Spurr L, Iorglescu B, Geduldig J, Birzu C, Lim Fat M, Santagata S, Coulet F, Beuvon F, Mokhtari K, Giry M, Block S, Guillerm E, ... ... Ligon K, et al. OS9.1 Clinical significance of hypermutation in gliomas Neuro-Oncology. 21: iii18-iii18. DOI: 10.1093/Neuonc/Noz126.059  0.38
2018 Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, ... ... Ligon KL, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. PMID 30568305 DOI: 10.1038/S41586-018-0792-9  0.309
2018 Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, et al. Vemurafenib and cobimetinib overcome resistance to vemurafenib in -mutant ganglioglioma. Neurology. PMID 30120137 DOI: 10.1212/Wnl.0000000000006171  0.4
2018 Jun HJ, Appleman VA, Wu HJ, Rose CM, Pineda JJ, Yeo AT, Delcuze B, Lee C, Gyuris A, Zhu H, Woolfenden S, Bronisz A, Nakano I, Chiocca EA, Bronson RT, ... Ligon KL, et al. A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nature Communications. 9: 3116. PMID 30082792 DOI: 10.1038/S41467-018-05036-4  0.353
2018 Kathagen-Buhmann A, Maire CL, Weller J, Schulte A, Matschke J, Holz M, Ligon KL, Glatzel M, Westphal M, Lamszus K. The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have antiproliferative effects. Neuro-Oncology. PMID 30053149 DOI: 10.1093/Neuonc/Noy117  0.312
2018 Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research. PMID 30002157 DOI: 10.1158/2326-6066.Cir-18-0067  0.338
2018 Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, et al. Dual HDAC and PI3K inhibition abrogates NFκB- and FOXM1-mediated DNA damage response to radiosensitize pediatric high-grade gliomas. Cancer Research. PMID 29760046 DOI: 10.1158/0008-5472.Can-17-3691  0.343
2018 Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S, Koelsche C, Schrimpf D, Niesen J, Wefers AK, Jones DTW, Sill M, Weigert O, Ligon KL, Olar A, et al. DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica. PMID 29730775 DOI: 10.1007/S00401-018-1854-7  0.324
2018 Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, ... ... Ligon KL, et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science (New York, N.Y.). 360: 331-335. PMID 29674595 DOI: 10.1126/Science.Aao4750  0.377
2018 Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, et al. Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology. PMID 29660006 DOI: 10.1093/Neuonc/Noy053  0.354
2018 Plant AS, Koyama S, Sinai C, Solomon IH, Griffin GK, Ligon KL, Bandopadhayay P, Betensky R, Emerson R, Dranoff G, Kieran MW, Ritz J. Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. Journal of Neuro-Oncology. PMID 29322427 DOI: 10.1007/S11060-017-2737-9  0.412
2018 Reardon DA, Neuberg DS, Keskin DB, Tirosh I, Anandappa A, Mathewson ND, Sun J, Shukla SA, Gjini E, Li S, Giobbie-Hurder A, Wucherpfennig K, Suva M, Fritsch E, Rodig S, ... Ligon KL, et al. Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine. Journal of Clinical Oncology. 36: 2020-2020. DOI: 10.1200/Jco.2018.36.15_Suppl.2020  0.346
2018 Iorgulescu B, Harary M, Zogg C, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith T. Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort. Journal of Clinical Oncology. 36: 2011-2011. DOI: 10.1200/Jco.2018.36.15_Suppl.2011  0.339
2018 Keskin DB, Tirosh I, Anandappa A, Sun J, Mathewson ND, Shukla SA, Gjini E, Li S, Li L, Giobbie-Hurder A, Le PM, Hu Z, Zhang W, Olive O, McCluskey C, ... ... Ligon KL, et al. Abstract 5631: Personal neoantigen-targeting vaccination generates neoepitope-specific T cell responses in tumors of patients with glioblastoma Cancer Research. 78: 5631-5631. DOI: 10.1158/1538-7445.Am2018-5631  0.345
2018 Ferrer-Luna R, Ramkissoon SH, Ramkissoon LA, Pellton K, Schumacher SE, Lamothe R, Cheah JH, Haidar S, Kang YJ, Knoff DS, Maire CL, Olausson KH, Song W, Idbaih A, Rinne ML, ... ... Ligon KL, et al. Abstract B077: Comprehensive molecular characterization and high-throughput chemical screening identifies genetic dependencies and molecular vulnerabilities in glioblastoma cell line models Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B077  0.378
2018 Pagès M, Rotem D, Gydush G, Reed S, Rhoades J, Ha G, Lo C, Tracy A, Jones R, Becker S, Haller M, Chi S, Kieran M, Goumnerova L, Love C, ... Ligon K, et al. Gene-07. Liquid Biopsy Detection Of Genomic Alterations In Pediatric Brain Tumors From Cell-Free Dna In Peripheral Blood, Csf, And Urine Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noz036.078  0.354
2018 Ahrendsen J, n MF, Chi S, Manley P, Wright K, Bandopadhayay P, Kieran M, Jones R, Ligon K, Alexandrescu S. Path-17. Increasing Value Of Autopsies In Patients With Brain Tumors In The Molecular Era Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.673  0.359
2018 De Smet F, Tseng Y, Ramkissoon S, Ramkissoon L, Pelton K, Luna RF, Panovska D, Schoolcraft K, Watkinson F, Bilton S, Hung V, Chow K, Geduldig J, Becker S, Jones R, ... ... Ligon K, et al. TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 20: vi271-vi271. DOI: 10.1093/Neuonc/Noy148.1126  0.383
2018 Robison N, Pauly J, Malvar J, Gruber-Filbin M, de Mola RL, Dorris K, Bendel A, Bowers D, Bornhorst M, Gauvain K, Leary S, Diaz P, Tan YJ, Margol A, Dhall G, ... ... Ligon K, et al. LGG-44. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS/RAF PATHWAY-ACTIVATED TUMORS Neuro-Oncology. 20: i114-i114. DOI: 10.1093/Neuonc/Noy059.385  0.32
2017 Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. Neuro-Oncology. PMID 29106665 DOI: 10.1093/Neuonc/Nox208  0.318
2017 Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski N, Taylor J, Clarke JL, Chang SM, et al. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29074604 DOI: 10.1158/1078-0432.Ccr-17-0963  0.314
2017 Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights Annals of Oncology. 28: 1457-1472. PMID 28863449 DOI: 10.1093/Annonc/Mdx106  0.394
2017 D'Aronco L, Rouleau C, Gayden T, Crevier L, Décarie JC, Perreault S, Jabado N, Bandopadhayay P, Ligon KL, Ellezam B. Brainstem angiocentric gliomas with MYB-QKI rearrangements. Acta Neuropathologica. PMID 28803398 DOI: 10.1007/S00401-017-1763-1  0.314
2017 Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, ... ... Ligon KL, et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016718726. PMID 28727518 DOI: 10.1200/Jco.2016.71.8726  0.393
2017 Coy S, Dubuc AM, Dahiya S, Ligon KL, Vasiljevic A, Santagata S. Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. The American Journal of Surgical Pathology. PMID 28719464 DOI: 10.1097/Pas.0000000000000903  0.381
2017 Bi WL, Greenwald NF, Ramkissoon SH, Abedalthagafi M, Coy SM, Ligon KL, Mei Y, MacConaill L, Ducar M, Min L, Santagata S, Kaiser UB, Beroukhim R, Laws ER, Dunn IF. Clinical identification of oncogenic drivers and copy number alterations in pituitary tumors. Endocrinology. PMID 28486603 DOI: 10.1210/En.2016-1967  0.415
2017 Bale TA, Oviedo A, Kozakewich H, Giannini C, Davineni PK, Ligon K, Alexandrescu S. Intracranial Myxoid Mesenchymal Tumors with EWSR1- CREB Family Gene Fusions: Myxoid Variant of Angiomatoid Fibrous Histiocytoma or Novel Entity? Brain Pathology (Zurich, Switzerland). PMID 28281318 DOI: 10.1111/Bpa.12504  0.378
2017 Liu L, Michowski W, Inuzuka H, Shimizu K, Nihira NT, Chick JM, Li N, Geng Y, Meng AY, Ordureau A, Kołodziejczyk A, Ligon KL, Bronson RT, Polyak K, Harper JW, et al. G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. Nature Cell Biology. PMID 28192421 DOI: 10.1038/Ncb3474  0.307
2017 Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF, Schumacher SE, O'Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A, Bi WL, Chang MS, ... ... Ligon KL, et al. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro-Oncology. PMID 28104717 DOI: 10.1093/Neuonc/Now294  0.345
2017 Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW, Ligon KL, Hahn WC, et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-Oncology. PMID 28082416 DOI: 10.1093/Neuonc/Now261  0.374
2017 Alexander BM, Trippa L, Gaffey SC, Arrillaga I, Lee EQ, Tanguturi SK, Ahluwalia MS, Colman H, Galanis E, Groot JFD, Drappatz J, Lassman AB, Nabors LB, Reardon DA, Schiff D, ... ... Ligon KL, et al. Individualized screening trial of innovative glioblastoma therapy (INSIGhT). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2079  0.354
2017 Sahebjam S, Ramkissoon S, Baehring JM, Mulholland PJ, Grauer OM, Cloughesy TF, Reardon DA, Lim M, Zwirtes RF, Latek RR, Strauss LC, Ligon KL. Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143. Journal of Clinical Oncology. 35: 2001-2001. DOI: 10.1200/Jco.2017.35.15_Suppl.2001  0.344
2017 Tseng Y(, Hong A, Gill S, Keskula P, Raghavan S, Cheah J, Tsherniak A, Vazquez F, Alkhairy S, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, Garraway L, ... ... Ligon K, et al. Abstract A02: Expanding tumor chemical-genetic interaction map using next-generation cancer models Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A02  0.352
2017 Ferrer-Luna R, Ramkissoon SH, Olausson KH, Ramkissoon LA, Schumacher S, Lamothe R, Cheah JH, Pellton K, Haidar S, Kang YJ, Paolella BR, Maire C, Song W, Meng A, Idbaih A, ... ... Ligon KL, et al. Abstract 4974: Pharmacogenomic interactions in glioblastoma cell line models Cancer Research. 77: 4974-4974. DOI: 10.1158/1538-7445.Am2017-4974  0.423
2017 Robison N, Pauly J, Malvar J, Filbin M, de Mola RL, Dorris K, Bendel A, Bowers D, Bornhorst M, Gauvain K, Leary S, MacDonald T, Gardner S, Reddy A, Diaz P, ... ... Ligon K, et al. PDCT-24. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS-RAF PATHWAY-ACTIVATED TUMORS: INITIAL REPORT Neuro-Oncology. 19: vi189-vi189. DOI: 10.1093/Neuonc/Nox168.765  0.327
2017 Linda Bi W, Greenwald N, Dubuc A, Santagata S, Ligon K, Ligon A, MacConnail L, Beroukhim R, Dunn I. PATH-30. GENOMIC LANDSCAPE OF CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 19: vi177-vi177. DOI: 10.1093/Neuonc/Nox168.720  0.353
2017 Ellingson B, Abrey L, Nelson S, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason W, Wick W, Butowski N, Ligon K, Gerstner E, Colman H, Taylor J, et al. NIMG-84. TUMOR LOCATION IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS Neuro-Oncology. 19: vi161-vi161. DOI: 10.1093/Neuonc/Nox168.654  0.366
2017 Ellingson B, Abrey L, Nelson S, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason W, Wick W, Butowski N, Ligon K, Gerstner E, Colman H, de Groot J, et al. NIMG-53. POST-SURGICAL, RESIDUAL ENHANCING TUMOR VOLUME IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS Neuro-Oncology. 19: vi154-vi154. DOI: 10.1093/Neuonc/Nox168.627  0.367
2017 Bandopadhayay P, Ramkissoon S, Hwang J, Ramkissoon L, Greenwald N, Schumacher S, O’Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A, Bi W, Chang M, ... ... Ligon K, et al. GENE-09. PRECISION MEDICINE ANALYSIS OF 203 PEDIATRIC BRAIN TUMORS REVEALS CLINICALLY RELEVANT GENOMIC ALTERATIONS Neuro-Oncology. 19: iv20-iv20. DOI: 10.1093/Neuonc/Nox083.080  0.382
2017 Haworth K, Boue DR, Folkerth R, Ligon KL, Tekautz T, Finlay JL. Bstm-02. Infantile Tectal Gliomas: Low-Grade Until Proven Otherwise Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox083.016  0.302
2016 Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, ... ... Ligon KL, et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology. PMID 28170043 DOI: 10.1093/Neuonc/Now235  0.409
2016 Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS, Kikuchi Y, Kimmerling RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbaih A, Wen PY, ... ... Ligon KL, et al. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nature Biotechnology. PMID 27723727 DOI: 10.1038/Nbt.3697  0.372
2016 Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, ... ... Ligon KL, et al. Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology. PMID 27683733 DOI: 10.1093/Neuonc/Now209  0.389
2016 Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, Marie Y, Bielle F, Mokhtari K, Hoang-Xuan K, Ligon K, Sanson M, Delattre JY, Idbaih A. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. Neuro-Oncology. PMID 27571888 DOI: 10.1093/Neuonc/Now160  0.39
2016 Bale TA, Abedalthagafi M, Bi WL, Kang YJ, Merrill P, Dunn IF, Dubuc A, Charbonneau SK, Brown L, Ligon AH, Ramkissoon SH, Ligon KL. Genomic characterization of recurrent high-grade astroblastoma. Cancer Genetics. PMID 27425854 DOI: 10.1016/J.Cancergen.2016.06.002  0.441
2016 Ni J, Xie S, Ramkissoon SH, Luu V, Sun Y, Bandopadhayay P, Beroukhim R, Roberts TM, Stiles CD, Segal RA, Ligon KL, Hahn WC, Zhao JJ. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro-Oncology. PMID 27402815 DOI: 10.1093/Neuonc/Now139  0.311
2016 Singh SK, Fiorelli R, Kupp R, Rajan S, Szeto E, Lo Cascio C, Maire CL, Sun Y, Alberta JA, Eschbacher JM, Ligon KL, Berens ME, Sanai N, Mehta S. Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway. Cell Reports. PMID 27396340 DOI: 10.1016/J.Celrep.2016.06.045  0.302
2016 Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, Ligon KL, Alexander BM, Wen PY, Huang RY. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro-Oncology. PMID 27353503 DOI: 10.1093/Neuonc/Now121  0.312
2016 Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, ... ... Ligon KL, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine. PMID 27270588 DOI: 10.1038/Nm.4120  0.37
2016 Miller MB, Bi WL, Ramkissoon LA, Kang YJ, Abedalthagafi M, Knoff DS, Agarwalla PK, Wen PY, Reardon DA, Alexander BM, Laws ER, Dunn IF, Beroukhim R, Ligon KL, Ramkissoon SH. MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. PMID 27175596 DOI: 10.18632/Oncotarget.9244  0.397
2016 Jahani-Asl A, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, Sincennes MC, Puram SV, Scott AM, Lorimer IA, Perkins TJ, Ligon KL, Weiss S, Rudnicki MA, Bonni A. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nature Neuroscience. PMID 27110918 DOI: 10.1038/Nn.4295  0.365
2016 Nikbakht H, Panditharatna E, Mikael LG, Li R, Gayden T, Osmond M, Ho CY, Kambhampati M, Hwang EI, Faury D, Siu A, Papillon-Cavanagh S, Bechet D, Ligon KL, Ellezam B, et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications. 7: 11185. PMID 27048880 DOI: 10.1038/Ncomms11185  0.34
2016 Dodgshun AJ, SantaCruz N, Hwang J, Ramkissoon SH, Malkin H, Bergthold G, Manley P, Chi S, MacGregor D, Goumnerova L, Sullivan M, Ligon K, Beroukhim R, Herrington B, Kieran MW, et al. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. Journal of Neuro-Oncology. PMID 26994902 DOI: 10.1007/S11060-016-2109-X  0.397
2016 Bandopadhayay P, Ramkissoon LA, Jain P, Bergthold G, Wala J, Zeid R, Schumacher SE, Urbanski L, O'Rourke R, Gibson WJ, Pelton K, Ramkissoon SH, Han HJ, Zhu Y, Choudhari N, ... ... Ligon KL, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics. PMID 26829751 DOI: 10.1038/Ng.3500  0.412
2016 Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, ... ... Ligon KL, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-Oncology. PMID 26826201 DOI: 10.1093/Neuonc/Nov316  0.343
2016 Diamandis P, Ferrer-Luna R, Huang RY, Folkerth RD, Ligon AH, Wen PY, Beroukhim R, Ligon KL, Ramkissoon SH. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagnostic Pathology. 11: 13. PMID 26817999 DOI: 10.1186/S13000-016-0455-9  0.45
2016 Huynh MA, Maire CL, Abazeed M, Lam FC, Adams D, Pelton K, Pinnell N, Knoff DC, Korideck H, Hummelen PV, Thorner A, Wen PY, Ligon A, Floyd SR, Schreiber SL, ... ... Ligon KL, et al. Functional profiling of a glioblastoma (GBM) patient-derived cell line (PDCL) panel to identify cell-intrinsic differential radiation response. Journal of Clinical Oncology. 34: 2069-2069. DOI: 10.1200/Jco.2016.34.15_Suppl.2069  0.361
2016 Prados M, Kuhn JG, Colman H, Cloughesy TF, Chang SM, Butowski NA, De Groot JF, Wen PY, Ligon KL, Mellinghoff IK, Chi AS, Phillips JJ, Molinaro AM, Halperin R, Tran N, et al. Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium. Journal of Clinical Oncology. 34: 2031-2031. DOI: 10.1200/Jco.2016.34.15_Suppl.2031  0.4
2016 Anderson SK, Miller CR, Sarkaria JN, Jaeckle KA, Buckner JC, Ligon KL, Ballman KV, Moore DF, Schiff D, Ahluwalia MS, Lee EQ, Horvath LE, Gerstner ER, Lesser GJ, Prados M, et al. Validating RNAseq-signatures of vorinostat (VOR) sensitivity and resistance in patients with newly diagnosed glioblastoma (GBM) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902. Journal of Clinical Oncology. 34: 2029-2029. DOI: 10.1200/Jco.2016.34.15_Suppl.2029  0.341
2016 Zhang B, Chang K, Ramkissoon S, Tanguturi SK, Bi WL, Reardon DA, Ligon KL, Alexander BM, Wen PY, Huang RY. Predicting isocitrate dehydrogenase genotype in malignant glioma with multimodality imaging markers. Journal of Clinical Oncology. 34: 2009-2009. DOI: 10.1200/Jco.2016.34.15_Suppl.2009  0.332
2016 Tseng Y, Keskula P, Hong AL, Gill S, Cheah JH, Kryukov GV, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, ... ... Ligon KL, et al. Abstract B26: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B26  0.36
2016 Ramkissoon L, Bandopadhayay P, Jain P, Bergthold G, Resnick A, Beroukhim R, Ligon K. Abstract 4372: MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism Cancer Research. 76: 4372-4372. DOI: 10.1158/1538-7445.Am2016-4372  0.414
2016 Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, ... ... Ligon K, et al. Abstract 4367: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Cancer Research. 76: 4367-4367. DOI: 10.1158/1538-7445.Am2016-4367  0.358
2016 Kieran MW, Sun Y, Pilarz C, Calligaris D, Chadwick EJ, Alberta JA, Ramkissoon SH, Ramkissoon LA, Garcia VM, Wilkinson K, Kane M, Goumnerova L, Chi SN, Manley P, Wright KD, ... ... Ligon KL, et al. LG-47TYPE II RAF INHIBITORS INHIBIT BRAF MUTATIONS AND TRUNCATED FUSIONS IN PEDIATRIC LOW-GRADE GLIOMAS Neuro-Oncology. 18: iii89.2-iii89. DOI: 10.1093/Neuonc/Now075.47  0.362
2016 Lassaletta A, Mistry M, Arnaldo A, Ryall S, Guerreiro-Stucklin A, Krishnatry R, Ling C, Honnorat M, Zhukova N, Zapotocky M, McKeown T, Ramaswamy V, Bartels U, Huang A, Jabado N, ... ... Ligon K, et al. Lg-46Inferior Outcome And Poor Response To Conventional Therapies In Pediatric Low-Grade Gliomas Harboring The Braf V600E Mutation. Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now075.46  0.316
2016 Rao AN, Kohorst M, Warad D, Ligon K, Daniels D, Raghunathan A, Sinai C, Ligon A, Giannini C. Lg-24Braf Alterations In Pediatric Pilocytic Astrocytomas With Recurrences/Progression Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now075.24  0.322
2016 Filbin MG, Tirosh I, Escalante LE, Venteicher AS, Goumnerova L, Pelton K, Bandopadhayay P, Mount C, Slavc I, Czech T, Gojo J, Lavarino C, Mora J, Monje M, Kieran MW, ... Ligon KL, et al. HG-110SINGLE-CELL TRANSCRIPTOME ANALYSIS IN PEDIATRIC HEMISPHERIC AND MIDLINE HIGH-GRADE GLIOMAS Neuro-Oncology. 18: iii74.1-iii74. DOI: 10.1093/Neuonc/Now073.106  0.328
2016 Bandopadhayay P, Ramkissoon S, Hwang J, Ramkissoon L, Dubuc A, Schumacher S, Janeway K, Pinches N, Malkin H, Sinai C, Manley P, Wright K, Filbin M, Goumnerova L, Alexandrescu S, ... ... Ligon K, et al. Ept-20Clinical Targeted Exome-Based Sequencing In Combination With Genome Wide Copy Number Profiling: A Clia Certified Approach For Precision Medicine In 203 Pediatric Brain Tumor Patients Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now069.19  0.381
2015 Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, ... ... Ligon KL, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. PMID 26702065 DOI: 10.1182/Blood-2015-10-673236  0.352
2015 Abedalthagafi MS, Wu MP, Merrill PH, Du Z, Woo T, Sheu SH, Hurwitz S, Ligon KL, Santagata S. Decreased FOXJ1 expression and its ciliogenesis program in aggressive ependymoma and choroid plexus tumours. The Journal of Pathology. PMID 26690880 DOI: 10.1002/Path.4682  0.319
2015 Chadwick EJ, Yang DP, Filbin MG, Mazzola E, Sun Y, Behar O, Pazyra-Murphy MF, Goumnerova L, Ligon KL, Stiles CD, Segal RA. A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. Journal of Visualized Experiments : Jove. PMID 26575352 DOI: 10.3791/53304  0.389
2015 Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Saur Conway A, Liao X, Zhou J, Wen PY, Van den Abbeele AD, Hodi FS, Qin L, Kohl NE, et al. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research. PMID 26546453 DOI: 10.1158/2326-6066.Cir-15-0151  0.301
2015 Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussiere M, Marie Y, Ligon AH, Mokhtari K, Hoang-Xuan K, Sanson M, Alexander BM, ... ... Ligon KL, et al. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26482041 DOI: 10.1158/1078-0432.Ccr-15-1015  0.381
2015 Bandopadhayay P, Silvera VM, Ciarlini PD, Malkin H, Bi WL, Bergthold G, Faisal AM, Ullrich NJ, Marcus K, Scott RM, Beroukhim R, Manley PE, Chi SN, Ligon KL, Goumnerova LC, et al. Myxopapillary ependymomas in children: imaging, treatment and outcomes. Journal of Neuro-Oncology. PMID 26468139 DOI: 10.1007/S11060-015-1955-2  0.309
2015 Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, ... Ligon KL, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology. PMID 26449250 DOI: 10.1093/Neuonc/Nov245  0.357
2015 Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery. PMID 26410082 DOI: 10.1158/2159-8290.Cd-15-0369  0.362
2015 Gutman DA, Dunn WD, Grossmann P, Cooper LA, Holder CA, Ligon KL, Alexander BM, Aerts HJ. Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology. PMID 26337765 DOI: 10.1007/S00234-015-1576-7  0.343
2015 Kang YJ, Bi WL, Dubuc AM, Martineau L, Ligon AH, Berkowitz AL, Aizer AA, Lee EQ, Ligon KL, Ramkissoon SH, Dunn IF. Integrated genomic characterization of a pineal parenchymal tumor of intermediate differentiation. World Neurosurgery. PMID 26226092 DOI: 10.1016/J.Wneu.2015.07.032  0.365
2015 Shankar GM, Francis JM, Rinne ML, Ramkissoon SH, Huang FW, Venteicher AS, Akama-Garren EH, Kang YJ, Lelic N, Kim JC, Brown LE, Charbonneau SK, Golby AJ, Sekhar Pedamallu C, Hoang MP, ... ... Ligon KL, et al. Rapid Intraoperative Molecular Characterization of Glioma. Jama Oncology. PMID 26181761 DOI: 10.1001/Jamaoncol.2015.0917  0.323
2015 Reardon DA, Ligon KL, Chiocca EA, Wen PY. One size should not fit all: advancing toward personalized glioblastoma therapy. Discovery Medicine. 19: 471-7. PMID 26175405  0.307
2015 Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology. 17: 1051-63. PMID 25934816 DOI: 10.1093/Neuonc/Nov031  0.369
2015 Kim D, Fiske BP, Birsoy K, Freinkman E, Kami K, Possemato RL, Chudnovsky Y, Pacold ME, Chen WW, Cantor JR, Shelton LM, Gui DY, Kwon M, Ramkissoon SH, Ligon KL, et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. 520: 363-7. PMID 25855294 DOI: 10.1038/Nature14363  0.368
2015 Bergthold G, Bandopadhayay P, Hoshida Y, Ramkissoon S, Ramkissoon L, Rich B, Maire CL, Paolella BR, Schumacher SE, Tabak B, Ferrer-Luna R, Ozek M, Sav A, Santagata S, Wen PY, ... ... Ligon KL, et al. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro-Oncology. PMID 25825052 DOI: 10.1093/Neuonc/Nov045  0.419
2015 Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, ... ... Ligon KL, et al. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology. PMID 25754088 DOI: 10.1093/Neuonc/Nov015  0.338
2015 Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN, Navickiene V, Mangerel J, Remke M, Buczkowicz P, Ramaswamy V, ... ... Ligon KL, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1015-22. PMID 25667294 DOI: 10.1200/Jco.2014.58.3922  0.345
2015 Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray MA, Viramontes O, Machaidze R, Brastianos PK, Reardon DA, Dunn IF, Freeman GJ, Ligon KL, Carpenter AE, Alexander BM, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 6: 4704-16. PMID 25609200 DOI: 10.18632/Oncotarget.3082  0.327
2015 Munoz JL, Rodriguez-Cruz V, Ramkissoon SH, Ligon KL, Greco SJ, Rameshwar P. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget. 6: 1190-201. PMID 25595896 DOI: 10.18632/Oncotarget.2778  0.319
2015 Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, ... ... Ligon KL, et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro-Oncology. 17: 862-7. PMID 25572329 DOI: 10.1093/Neuonc/Nou350  0.307
2015 Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, et al. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 585-93. PMID 25473003 DOI: 10.1158/1078-0432.Ccr-13-1711  0.381
2015 Green AL, Ramkissoon SH, McCauley D, Jones K, Perry JA, Hsu JH, Ramkissoon LA, Maire CL, Hubbell-Engler B, Knoff DS, Shacham S, Ligon KL, Kung AL. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro-Oncology. 17: 697-707. PMID 25366336 DOI: 10.1093/Neuonc/Nou303  0.359
2015 Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, ... ... Ligon KL, et al. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. Journal of Neuro-Oncology. 121: 297-302. PMID 25338318 DOI: 10.1007/S11060-014-1631-Y  0.32
2015 Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, ... ... Ligon KL, et al. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro-Oncology. 17: 180-8. PMID 25165194 DOI: 10.1093/Neuonc/Nou154  0.312
2015 Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology. 17: 116-21. PMID 25100872 DOI: 10.1093/Neuonc/Nou148  0.41
2015 Chen C, Kozono D, Li J, Nitta M, Sampetrean O, Ng K, Gonda D, Kushwaha DS, Merzon D, Ramakrishnan V, Zhu S, Zhu K, Matsui H, Harismendy O, Hua W, ... ... Ligon KL, et al. Abstract PR02: Dynamic epigenetic regulation of glioblastoma tumorigenicity through a LSD1-MYC-OLIG2 axis Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Pr02  0.344
2015 Berger AH, Kim E, Brooks A, Ilic N, Shrestha Y, Tseng Y, Wu X, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Kantoff P, ... Ligon KL, et al. Abstract PR07: Towards precision functional genomics via next-generation functional mapping of cancer variants Cancer Research. 75: 957-957. DOI: 10.1158/1538-7445.Transcagen-Pr07  0.343
2015 Kozono D, Li J, Nitta M, Sampetrean O, Ng K, Gonda D, Kushwaha D, Hiroko M, Harismendy O, Becher O, Kwon C, Ligon KL, Saya H, Carter BS, Pizzo D, et al. Abstract PR13: Epigenetic regulation of MYC drives dynamic transition between tumor initiating states in glioblastoma Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-Pr13  0.397
2015 Brastianos PK, Carter SL, Santagata S, Taylor-Weiner A, Jones RT, Allen EV, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Cahill D, Curry WT, Dunn IF, Paek SH, Hummelen PV, et al. Abstract 4727: Genomic characterization of brain metastases reveals divergent evolution and metastasis specific mutations Brain. 75: 4727-4727. DOI: 10.1158/1538-7445.Am2015-4727  0.353
2015 Ferrer-Luna R, Ramkissoon SH, Ramkissoon LA, Lamothe R, Cheah JH, Schumacher SE, Haidar S, Clemons PA, Shamji A, Ligon KL, Beroukhim R. Abstract B66: Identification of genetic and non-genetic dependencies in glioblastoma cell lines targeted by small molecules Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B66  0.419
2015 Filbin MG, Tirosh I, Escalante LE, Venteicher AS, Hebert C, Goumnerova L, Ligon KL, Golub T, Regev A, Suva ML. PTPS-06SINGLE-CELL TRANSCRIPTOME ANALYSIS IN PEDIATRIC HIGH-GRADE GLIOMA Neuro-Oncology. 17: v180.2-v180. DOI: 10.1093/Neuonc/Nov228.06  0.42
2015 Ramkissoon S, Sampson J, Vlahovic G, Sahebjam S, Omuro A, Baehring J, Latek R, Vandeloise E, Coric V, Cloughesy T, Lim M, Reardon D, Ligon K. NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143 Neuro-Oncology. 17: v156.4-v157. DOI: 10.1093/Neuonc/Nov225.17  0.354
2015 Jahani-Asl A, Yin H, Soleimani V, Chang N, Sincennes M, Luchman HA, Sidharth P, Scott A, Lorimer I, Perkins T, Ligon K, Weiss S, Rudnicki M, Bonni A. CSIG-06EGFRvIII REQUIRES OSMR AS A CO-RECEPTOR TO DRIVE GLIOBLASTOMA PATHOGENESIS Neuro-Oncology. 17: v67.2-v67. DOI: 10.1093/Neuonc/Nov210.06  0.382
2015 Brastianos P, Carter S, Santagata S, Cahill D, Taylor-Weiner A, Jones R, Ligon K, Tabernero J, Seoane J, Martinez Saez E, Johnson B, Choueiri T, Stemmer-Rachamimov A, Lin N, Beroukhim R, et al. 2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets European Journal of Cancer. 51: S586. DOI: 10.1016/S0959-8049(16)31622-7  0.379
2015 Huynh M, Maire C, Abazeed M, Adams D, Pelton K, Pinnell N, Ramkissoon S, Korideck H, Van Hummelen P, Thorner A, Wen P, Ligon A, Schreiber S, Meyerson M, Ligon K, et al. Functional Profiling of a Glioblastoma (GBM) Patient-Derived Cell Line (PDCL) Panel Identifies Cell-Intrinsic Differential Radiation Response That Correlates With TP53 Mutations International Journal of Radiation Oncology*Biology*Physics. 93: E91-E92. DOI: 10.1016/J.Ijrobp.2015.07.779  0.336
2014 Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC, Sarkaria JN. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology. PMID 25526733 DOI: 10.1093/Neuonc/Nou328  0.325
2014 Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT. Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. British Journal of Cancer. 111: 2275-86. PMID 25375271 DOI: 10.1038/Bjc.2014.529  0.311
2014 Abedalthagafi MS, Merrill PH, Bi WL, Jones RT, Listewnik ML, Ramkissoon SH, Thorner AR, Dunn IF, Beroukhim R, Alexander BM, Brastianos PK, Francis JM, Folkerth RD, Ligon KL, Van Hummelen P, et al. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 5: 10596-606. PMID 25347344 DOI: 10.18632/Oncotarget.2517  0.312
2014 Maire CL, Ligon KL. Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro-Oncology. 16: viii1-6. PMID 25342599 DOI: 10.1093/Neuonc/Nou294  0.343
2014 Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, ... ... Ligon KL, et al. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 5: 8083-92. PMID 25257301 DOI: 10.18632/Oncotarget.2342  0.411
2014 Bechet D, Gielen GG, Korshunov A, Pfister SM, Rousso C, Faury D, Fiset PO, Benlimane N, Lewis PW, Lu C, David Allis C, Kieran MW, Ligon KL, Pietsch T, Ellezam B, et al. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathologica. 128: 733-41. PMID 25200321 DOI: 10.1007/S00401-014-1337-4  0.401
2014 Holmberg Olausson K, Maire CL, Haidar S, Ling J, Learner E, Nistér M, Ligon KL. Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas. Plos One. 9: e106694. PMID 25184684 DOI: 10.1371/Journal.Pone.0106694  0.369
2014 Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, et al. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology. 16: 1541-6. PMID 24997140 DOI: 10.1093/Neuonc/Nou083  0.347
2014 Santagata S, Eberlin LS, Norton I, Calligaris D, Feldman DR, Ide JL, Liu X, Wiley JS, Vestal ML, Ramkissoon SH, Orringer DA, Gill KK, Dunn IF, Dias-Santagata D, Ligon KL, et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proceedings of the National Academy of Sciences of the United States of America. 111: 11121-6. PMID 24982150 DOI: 10.1073/Pnas.1404724111  0.343
2014 Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA, Corcoran A, Jones DT, Sturm D, Johann P, Tomita T, ... ... Ligon KL, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics. 46: 462-6. PMID 24705250 DOI: 10.1038/Ng.2950  0.392
2014 Lee JW, Norden AD, Ligon KL, Golby AJ, Beroukhim R, Quackenbush J, Wells W, Oelschlager K, Maetzold D, Wen PY. Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. Epilepsy Research. 108: 843-52. PMID 24690158 DOI: 10.1016/J.Eplepsyres.2014.02.021  0.354
2014 Munoz JL, Rodriguez-Cruz V, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death & Disease. 5: e1145. PMID 24675463 DOI: 10.1038/Cddis.2014.111  0.37
2014 Watanabe H, Ma Q, Peng S, Adelmant G, Swain D, Song W, Fox C, Francis JM, Pedamallu CS, DeLuca DS, Brooks AN, Wang S, Que J, Rustgi AK, Wong KK, ... Ligon KL, et al. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. The Journal of Clinical Investigation. 124: 1636-45. PMID 24590290 DOI: 10.1172/Jci71545  0.322
2014 Bergthold G, Bandopadhayay P, Bi WL, Ramkissoon L, Stiles C, Segal RA, Beroukhim R, Ligon KL, Grill J, Kieran MW. Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochimica Et Biophysica Acta. 1845: 294-307. PMID 24589977 DOI: 10.1016/J.Bbcan.2014.02.004  0.408
2014 Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, ... ... Ligon KL, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology. 16: 567-78. PMID 24470557 DOI: 10.1093/Neuonc/Not247  0.363
2014 Chudnovsky Y, Kim D, Zheng S, Whyte WA, Bansal M, Bray MA, Gopal S, Theisen MA, Bilodeau S, Thiru P, Muffat J, Yilmaz OH, Mitalipova M, Woolard K, Lee J, ... ... Ligon KL, et al. ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Reports. 6: 313-24. PMID 24440720 DOI: 10.1016/J.Celrep.2013.12.032  0.374
2014 Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L, Sunkavalli A, Shillingford N, Calicchio ML, Lidov HG, Taha H, ... ... Ligon KL, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genetics. 46: 161-5. PMID 24413733 DOI: 10.1038/Ng.2868  0.392
2014 Maire CL, Ramkissoon S, Hayashi M, Haidar S, Ramkissoon L, DiTomaso E, Ligon KL. Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy. Stem Cells (Dayton, Ohio). 32: 313-26. PMID 24395742 DOI: 10.1002/Stem.1590  0.329
2014 Reardon DA, Gokhale PC, Hodi FS, Ligon KL, Liao X, Rodig SJ, Zhou J, Qin L, Jones K, Sauer A, Kohl NE, Dranoff G, Freeman GJ. Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy. Journal of Clinical Oncology. 32: 2084-2084. DOI: 10.1200/Jco.2014.32.15_Suppl.2084  0.33
2014 Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Smith KH, Gaffey SC, McCluskey CS, Ligon KL, Reardon DA, et al. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results. Journal of Clinical Oncology. 32: 2053-2053. DOI: 10.1200/Jco.2014.32.15_Suppl.2053  0.324
2014 Butowski NA, Colman H, De Groot JF, Omuro AMP, Nayak L, Cloughesy TF, Marimuthu A, Perry A, Phillips JJ, West B, Prados M, Nolop KB, Hsu HH, Ligon KL. A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma. Journal of Clinical Oncology. 32: 2023-2023. DOI: 10.1200/Jco.2014.32.15_Suppl.2023  0.377
2014 Wen PY, Yung WKA, Mellinghoff IK, Ramkissoon S, Alexander BM, Rinne ML, Colman H, Omuro AMP, DeAngelis LM, Gilbert MR, De Groot JF, Cloughesy TF, Chi AS, Lee EQ, Nayak L, ... ... Ligon KL, et al. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma. Journal of Clinical Oncology. 32: 2019-2019. DOI: 10.1200/Jco.2014.32.15_Suppl.2019  0.373
2014 Ramkissoon S, Bi WL, Haidar S, Cryan JB, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Russo AL, Arvold ND, Santagata S, Dunn IF, Folkerth RD, Lindeman NI, ... ... Ligon KL, et al. Integrative whole-genome copy number analysis and mutation profiling of FFPE brain tumor specimens and potential in designing multi-arm clinical trials. Journal of Clinical Oncology. 32: 11098-11098. DOI: 10.1200/Jco.2014.32.15_Suppl.11098  0.36
2014 Brastianos PK, Carter SL, Santagata S, Taylor-Weiner A, Jones RT, Horowitz PM, Ligon KL, Seaone J, Martinez-Saez E, Tabernero J, Cahill DP, Paek S, Dunn IF, Johnson BE, Choueiri TK, et al. Abstract NG03: Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ng03  0.417
2014 Watanabe H, Ma Q, Peng S, Adelmant G, Swain D, Song W, Fox C, Francis JM, Pedamallu CS, Deluca DS, Brooks AN, Que J, Rustgi AK, Wong K, Ligon KL, et al. Abstract 1391: SOX2-p63 interaction and genomic co-localization in squamous cell carcinomas Cancer Research. 74: 1391-1391. DOI: 10.1158/1538-7445.Am2014-1391  0.319
2014 Reardon D, Gokhale P, Ligon K, Liao X, Rodig S, Zhou J, Qin L, Hodi S, Jones K, Sauer A, Kohl N, Dranoff G, Freeman G. It-29Immune Checkpoint Blockade For Glioblastoma: Preclinical Activity Of Single Agent And Combinatorial Therapy Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou258.27  0.348
2014 Bandopadhayay P, Chi S, Janeway K, Pinches N, Malkin H, Manley P, Goumnerova L, Chang M, Kieran M, Harris M, Ramkissoon S, Ligon K. Ge-02Clinical Targeted Exome-Based Sequencing For Children Diagnosed With Brain Tumors: Initial Results Of An Institute-Wide Project On Personalized Medicine Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou256.2  0.436
2014 Verreault M, Levasseur C, Schmitt C, Guehennec J, Labussiere M, Marie Y, Haidar S, Mokhtari K, Hoang-Xuan K, Sanson M, Ligon K, Delattre J, Idbaih A. Et-62Highly Selective Activity Of Mdm2 Inhibitor Rg7112 Against Mdm2-Amplified/Tp53 Wild-Type Glioblastomas Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou255.59  0.394
2014 Chen C, Kozono D, Li J, Nitta M, Sampetrean O, Gonda D, Kushwaha D, Vandenberg S, Ramakrishnan V, Zhu S, Furnari F, Matsui H, Harismendy O, Cavenee W, Mao Y, ... ... Ligon K, et al. CB-04 * EPIGENETIC REGULATION OF GLIOBLASTOMA TUMORIGENICITY: A HYBRID MODEL Neuro-Oncology. 16: v41-v41. DOI: 10.1093/Neuonc/Nou241.4  0.373
2014 Brastianos P, Carter S, Santagata S, Taylor-Weiner A, Jones R, Van Allen E, Horowitz P, Ligon K, Cahill D, Dunn I, Van Hummelen P, Lin N, Curry W, Stemmer-Rachamimov A, Beroukhim R, et al. BM-07 * GENOMIC CHARACTERIZATION OF BRAIN METASTASES REVEALS BRANCHED EVOLUTION AND METASTASIS-SPECIFIC MUTATIONS Neuro-Oncology. 16: v33-v33. DOI: 10.1093/Neuonc/Nou240.7  0.401
2014 Ma D, Galanis E, Peller P, Ligon K, Giannini C, Sarkaria J. Bi-20Genetic Profiling For Early Everolimus Sensitivity In Newly Diagnosed Glioblastoma Patients Enrolled On Ncctg N057K. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou239.20  0.36
2014 Lee E, Reardon D, Schiff D, Drappatz J, Muzikansky A, Grimm S, Norden A, Nayak L, Beroukhim R, Rinne M, Chi A, Batchelor T, Hempfling K, McCluskey C, Smith K, ... ... Ligon K, et al. At-36Panobinostat In Combination With Bevacizumab For Recurrent Glioblastoma And Anaplastic Glioma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.36  0.317
2014 Wen PY, Wen PY, Yung WKA, Mellinghoff IK, Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro AM, DeAngelis LM, Gilbert MR, DeGroot J, Cloughesy TF, Lee EQ, Nayak L, ... ... Ligon KL, et al. PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM Neuro-Oncology. 16: iii47-iii47. DOI: 10.1093/Neuonc/Nou209.20  0.419
2013 Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schüller U, Gururangan S, McLendon R, Bigner D, Fouladi M, ... Ligon KL, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet. Oncology. 14: 1200-7. PMID 24140199 DOI: 10.1016/S1470-2045(13)70449-2  0.301
2013 Filbin MG, Dabral SK, Pazyra-Murphy MF, Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y, Franchetti Y, Sun Y, Shulman DS, Redjal N, Tabak B, Beroukhim R, ... ... Ligon KL, et al. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nature Medicine. 19: 1518-23. PMID 24076665 DOI: 10.1038/Nm.3328  0.344
2013 Ji M, Orringer DA, Freudiger CW, Ramkissoon S, Liu X, Lau D, Golby AJ, Norton I, Hayashi M, Agar NY, Young GS, Spino C, Santagata S, Camelo-Piragua S, Ligon KL, et al. Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Science Translational Medicine. 5: 201ra119. PMID 24005159 DOI: 10.1126/Scitranslmed.3005954  0.361
2013 Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, ... ... Ligon KL, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics. 45: 927-32. PMID 23817572 DOI: 10.1038/Ng.2682  0.429
2013 Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, Schumacher SE, McKenna A, Lawrence MS, Bergthold G, Brastianos PK, Tabak B, Ducar MD, Van Hummelen P, MacConaill LE, Pouissant-Young T, ... ... Ligon KL, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proceedings of the National Academy of Sciences of the United States of America. 110: 8188-93. PMID 23633565 DOI: 10.1073/Pnas.1300252110  0.4
2013 Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C, Venneti S, Zadeh G, Santi M, Zhou S, Appin CL, Sioletic S, Sullivan LM, et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathology (Zurich, Switzerland). 23: 565-73. PMID 23438035 DOI: 10.1111/Bpa.12043  0.362
2013 Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nature Genetics. 45: 285-9. PMID 23334667 DOI: 10.1038/Ng.2526  0.425
2013 Eberlin LS, Norton I, Orringer D, Dunn IF, Liu X, Ide JL, Jarmusch AK, Ligon KL, Jolesz FA, Golby AJ, Santagata S, Agar NY, Cooks RG. Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 110: 1611-6. PMID 23300285 DOI: 10.1073/Pnas.1215687110  0.387
2013 Katz SG, Fisher JK, Correll M, Bronson RT, Ligon KL, Walensky LD. Brain and testicular tumors in mice with progenitor cells lacking BAX and BAK. Oncogene. 32: 4078-85. PMID 22986529 DOI: 10.1038/Onc.2012.421  0.34
2013 Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Muzikansky A, Dietrich J, Smith KH, Gaffey SC, McCluskey CS, Ligon KL, Reardon DA, Wen PY. Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps2104  0.319
2013 Alexander BM, Ramkissoon S, Wen PY, Reardon DA, Lee EQ, Rinne M, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Brown LE, Arvold ND, Dunn IF, Santagata S, ... ... Ligon KL, et al. Combined whole genome copy number genotyping and multiplex somatic mutation profiling of FFPE brain tumor specimens for clinical diagnosis and trial selection. Journal of Clinical Oncology. 31: 2030-2030. DOI: 10.1200/Jco.2013.31.15_Suppl.2030  0.405
2013 Wen PY, Yung WKA, Mellinghoff IK, Lamborn K, Ramkissoon S, Cloughesy TF, Rinne M, Omuro AMP, DeAngelis LM, Gilbert MR, Chi AS, Batchelor T, Colman H, Chang SM, Massacesi C, ... ... Ligon KL, et al. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). Journal of Clinical Oncology. 31: 2015-2015. DOI: 10.1200/Jco.2013.31.15_Suppl.2015  0.435
2013 Brastianos P, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon K, Hummelen PV, Ducar M, Raza A, Sunkavalli A, MacConaill L, Stemmer-Rachamimov A, Louis DN, Hahn WC, et al. Abstract 803: Genomic sequencing of meningiomas reveals oncogenic SMO and AKT1 mutations. Cancer Research. 73: 803-803. DOI: 10.1158/1538-7445.Am2013-803  0.426
2013 Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Lambert SR, Quang DAK, Fontebasso AM, Ryzhova M, Warnatz H, Zichner T, Korbel JO, Wolf S, Yaspo M, Ligon KL, et al. Abstract 4594: Recurrent FGFR1 hotspot mutations represent a novel therapeutic target in childhood astrocytoma. Cancer Research. 73: 4594-4594. DOI: 10.1158/1538-7445.Am2013-4594  0.428
2013 Ferrer-Luna R, Ramkissoon S, Cheah J, Lamothe R, Schumacher S, Shamji A, Clemons P, Reardon D, Wen P, Schreiber S, Ligon K, Beroukhim R. Abstract A103: High-throughput genomic and chemical screening in glioblastoma cell lines. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A103  0.363
2013 Arvold ND, Wen PY, Reardon DA, Lee EQ, Pinnell NE, Christianson LW, Weiss SE, Dunn IF, Ligon KL, Alexander BM. Disconnect Between Recurrence-Free Survival and Overall Survival for Newly Diagnosed Glioblastoma Patients Receiving Adjuvant Bevacizumab International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.049  0.305
2012 Quayle SN, Lee JY, Cheung LW, Ding L, Wiedemeyer R, Dewan RW, Huang-Hobbs E, Zhuang L, Wilson RK, Ligon KL, Mills GB, Cantley LC, Chin L. Somatic mutations of PIK3R1 promote gliomagenesis. Plos One. 7: e49466. PMID 23166678 DOI: 10.1371/Journal.Pone.0049466  0.384
2012 Quayle SN, Chheda MG, Shukla SA, Wiedemeyer R, Tamayo P, Dewan RW, Zhuang L, Huang-Hobbs E, Haidar S, Xiao Y, Ligon KL, Hahn WC, Chin L. Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro-Oncology. 14: 1325-31. PMID 23074196 DOI: 10.1093/Neuonc/Nos246  0.307
2012 Kieran MW, Roberts CW, Chi SN, Ligon KL, Rich BE, Macconaill LE, Garraway LA, Biegel JA. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatric Blood & Cancer. 59: 1155-7. PMID 22997201 DOI: 10.1002/Pbc.24315  0.42
2012 Rodriguez FJ, Ligon AH, Horkayne-Szakaly I, Rushing EJ, Ligon KL, Vena N, Garcia DI, Cameron JD, Eberhart CG. BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. Journal of Neuropathology and Experimental Neurology. 71: 789-94. PMID 22892521 DOI: 10.1097/Nen.0B013E3182656Ef8  0.359
2012 Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. Journal of Neuro-Oncology. 110: 89-98. PMID 22821383 DOI: 10.1007/S11060-012-0938-9  0.401
2012 Shin J, Padmanabhan A, de Groh ED, Lee JS, Haidar S, Dahlberg S, Guo F, He S, Wolman MA, Granato M, Lawson ND, Wolfe SA, Kim SH, Solnica-Krezel L, Kanki JP, ... Ligon KL, et al. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Disease Models & Mechanisms. 5: 881-94. PMID 22773753 DOI: 10.1242/Dmm.009779  0.358
2012 Hasselblatt M, Kordes U, Wolff J, Jeibmann A, Frühwald M, Paulus W, Isken S, Siebert R, Schneppenheim R, Benesch M, Fleischhack G, Gruhn B, Schlegel P, Witt O, Holter W, ... ... Ligon KL, et al. Atypical Teratoid Rhabdoid Tumor (Atrt) Neuro-Oncology. 14. PMID 22745951 DOI: 10.1093/Neuonc/Nos091  0.356
2012 Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, ... Ligon KL, et al. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. Plos One. 7: e38881. PMID 22719973 DOI: 10.1371/Journal.Pone.0038881  0.307
2012 Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro-Oncology. 14: 761-7. PMID 22661585 DOI: 10.1093/Neuonc/Nos065  0.339
2012 Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-Oncology. 14: 819-29. PMID 22619466 DOI: 10.1093/Neuonc/Nos117  0.393
2012 Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes & Development. 26: 756-84. PMID 22508724 DOI: 10.1101/Gad.187922.112  0.369
2012 Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BF, Riviello JJ, Barkovich AJ, Black PM, ... Ligon KL, et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 74: 41-8. PMID 22500628 DOI: 10.1016/J.Neuron.2012.03.010  0.343
2012 Rodriguez FJ, Orr BA, Ligon KL, Eberhart CG. Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget. 3: 98-106. PMID 22298889 DOI: 10.18632/Oncotarget.427  0.363
2012 Eberlin LS, Norton I, Dill AL, Golby AJ, Ligon KL, Santagata S, Cooks RG, Agar NY. Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Research. 72: 645-54. PMID 22139378 DOI: 10.1158/0008-5472.Can-11-2465  0.357
2012 Brastianos PK, Horowitz P, Santagata S, Jones RT, McKenna A, Ligon K, Palescandolo E, Van Hummelen P, Getz G, Hahn WC, Dunn IF, Beroukhim R. Genomic characterization of meningiomas. Journal of Clinical Oncology. 30: 2020-2020. DOI: 10.1200/Jco.2012.30.15_Suppl.2020  0.434
2012 Kozono D, Nitta M, Sampetrean O, Ng K, Merzon D, Kushwaha D, Zhu K, Ligon K, Zhu S, Saya H, Chen CC. Abstract 5218: A c-Myc driven threshold model of tumor initiating in glioblastoma Cancer Research. 72: 5218-5218. DOI: 10.1158/1538-7445.Am2012-5218  0.362
2012 Amakye D, Robinson D, Rose K, Cho J, Ligon KL, Sharp T, Haider A, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley D, Hargrave D, Casanova M, Rodon J, et al. Abstract 4818: The predictive value of a 5-gene signature as a patient pre-selection tool in medulloblastoma for Hedgehog pathway inhibitor therapy Cancer Research. 72: 4818-4818. DOI: 10.1158/1538-7445.Am2012-4818  0.403
2012 Katz SG, Fisher JK, Bronson RT, Ligon KL, Walensky LD. Abstract 2367: Neural progenitor cells deficient in BAX and BAK manifest progressive hyperplasia and tumorigenesis Cancer Research. 72: 2367-2367. DOI: 10.1158/1538-7445.Am2012-2367  0.333
2012 Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Gregory Cairncross J, Urgoiti GBR, Wen PY, Ligon KL, Schiff D, et al. Response to Weltman and Fleury Malheiros, re Lassman et al. Neuro-Oncology. 14: 677-678. DOI: 10.1093/Neuonc/Nos136  0.357
2011 Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, Goldman S, Taha H, Mahmoud M, Ozek M, Sav A, Longtine JA, Lindeman NI, Garraway LA, Ligon AH, ... ... Ligon KL, et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. The Journal of Molecular Diagnostics : Jmd. 13: 669-77. PMID 21884820 DOI: 10.1016/J.Jmoldx.2011.07.002  0.384
2011 Okamoto N, Yasukawa M, Nguyen C, Kasim V, Maida Y, Possemato R, Shibata T, Ligon KL, Fukami K, Hahn WC, Masutomi K. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proceedings of the National Academy of Sciences of the United States of America. 108: 20388-93. PMID 21730156 DOI: 10.1073/Pnas.1015171108  0.39
2011 Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. Plos One. 6: e17948. PMID 21479234 DOI: 10.1371/Journal.Pone.0017948  0.414
2011 Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 19: 359-71. PMID 21397859 DOI: 10.1016/J.Ccr.2011.01.035  0.314
2011 Maire CL, Ligon KL. Glioma models: new GEMMs add "class" with genomic and expression correlations. Cancer Cell. 19: 295-7. PMID 21397851 DOI: 10.1016/J.Ccr.2011.02.018  0.348
2011 Agar NY, Golby AJ, Ligon KL, Norton I, Mohan V, Wiseman JM, Tannenbaum A, Jolesz FA. Development of stereotactic mass spectrometry for brain tumor surgery. Neurosurgery. 68: 280-89; discussion 2. PMID 21135749 DOI: 10.1227/Neu.0B013E3181Ff9Cbb  0.371
2011 Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, ... ... Ligon K, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1424-30. PMID 21098324 DOI: 10.1200/Jco.2010.28.5148  0.363
2011 Maire CL, Ramkissoon SH, Ligon KL. Abstract 3304: Conditional Pten loss in Olig2 expressing neural stem/progenitor cells results in massive myelination and disruption of the neuronal differentiation in the absence of neoplasia Cancer Research. 71: 3304-3304. DOI: 10.1158/1538-7445.Am2011-3304  0.362
2011 Kozono D, Nitta M, Ng K, Zinn PO, Kushwaha D, Koay D, Merzon D, Zhu K, Zhu S, Ligon K, Chen C. Abstract 3301: c-Myc modulates the dynamic transition between tumor initiating states in glioblastoma Cancer Research. 71: 3301-3301. DOI: 10.1158/1538-7445.Am2011-3301  0.381
2010 Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proceedings of the National Academy of Sciences of the United States of America. 107: 2616-21. PMID 20133782 DOI: 10.1073/Pnas.0914356107  0.401
2010 Idbaih A, Crinière E, Ligon KL, Delattre O, Delattre JY. Array-based genomics in glioma research. Brain Pathology (Zurich, Switzerland). 20: 28-38. PMID 19298630 DOI: 10.1111/J.1750-3639.2009.00274.X  0.302
2010 MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, ... ... Ligon KL, et al. Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples Plos One. 5. DOI: 10.1371/Annotation/3A0C8Fee-57Ef-43Ed-B6C2-55B503E6Db5E  0.332
2009 Santagata S, Maire CL, Idbaih A, Geffers L, Correll M, Holton K, Quackenbush J, Ligon KL. CRX is a diagnostic marker of retinal and pineal lineage tumors. Plos One. 4: e7932. PMID 19936203 DOI: 10.1371/Journal.Pone.0007932  0.395
2009 MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, ... ... Ligon KL, et al. Profiling critical cancer gene mutations in clinical tumor samples. Plos One. 4: e7887. PMID 19924296 DOI: 10.1371/Journal.Pone.0007887  0.385
2009 Paik JH, Ding Z, Narurkar R, Ramkissoon S, Muller F, Kamoun WS, Chae SS, Zheng H, Ying H, Mahoney J, Hiller D, Jiang S, Protopopov A, Wong WH, Chin L, ... Ligon KL, et al. FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell. 5: 540-53. PMID 19896444 DOI: 10.1016/J.Stem.2009.09.013  0.314
2009 Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, ... Ligon KL, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology. 11: 853-60. PMID 19293394 DOI: 10.1215/15228517-2009-010  0.355
2009 Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 330-7. PMID 19118062 DOI: 10.1158/1078-0432.Ccr-08-0888  0.352
2008 Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, ... ... Ligon KL, et al. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harbor Symposia On Quantitative Biology. 73: 427-37. PMID 19150964 DOI: 10.1101/Sqb.2008.73.047  0.412
2008 Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, ... ... Ligon KL, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 455: 1129-33. PMID 18948956 DOI: 10.1038/Nature07443  0.388
2008 Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Huillard E, Sun T, Ligon AH, Qian Y, Ma Q, Alvarez-Buylla A, McMahon AP, Rowitch DH, Ligon KL. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 14: 123-34. PMID 18691547 DOI: 10.1016/J.Ccr.2008.07.005  0.34
2008 Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncology. 10: 300-8. PMID 18403492 DOI: 10.1215/15228517-2008-005  0.319
2008 Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F, Cavenee WK, Hahn WC, Ichimura K, Collins VP, Chu GC, Stratton MR, ... Ligon KL, et al. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 13: 355-64. PMID 18394558 DOI: 10.1016/J.Ccr.2008.02.010  0.325
2007 Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes & Development. 21: 2683-710. PMID 17974913 DOI: 10.1101/Gad.1596707  0.394
2007 Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (New York, N.Y.). 318: 287-90. PMID 17872411 DOI: 10.1126/Science.1142946  0.398
2007 Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. The American Journal of Surgical Pathology. 31: 836-45. PMID 17527070 DOI: 10.1097/Pas.0B013E31802E708A  0.356
2007 Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, Anderson DJ, Stiles CD, Rowitch DH. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 53: 503-17. PMID 17296553 DOI: 10.1016/J.Neuron.2007.01.009  0.356
2006 Rousseau A, Nutt CL, Betensky RA, Iafrate AJ, Han M, Ligon KL, Rowitch DH, Louis DN. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Journal of Neuropathology and Experimental Neurology. 65: 1149-56. PMID 17146289 DOI: 10.1097/01.Jnen.0000248543.90304.2B  0.351
2006 Santagata S, Hornick JL, Ligon KL. Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. The American Journal of Surgical Pathology. 30: 1613-8. PMID 17122519 DOI: 10.1097/01.Pas.0000213320.04919.1A  0.314
2006 Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, Richardson A, Khatry D, Feng B, Sinha R, Louis DN, Quackenbush J, Black PM, Chin L, DePinho RA. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Research. 66: 11502-13. PMID 17114236 DOI: 10.1158/0008-5472.Can-06-2072  0.365
2006 Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, McMahon AP. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Research. 66: 10171-8. PMID 17047082 DOI: 10.1158/0008-5472.Can-06-0657  0.384
2006 Ligon KL, Kesari S, Kitada M, Sun T, Arnett HA, Alberta JA, Anderson DJ, Stiles CD, Rowitch DH. Development of NG2 neural progenitor cells requires Olig gene function. Proceedings of the National Academy of Sciences of the United States of America. 103: 7853-8. PMID 16682644 DOI: 10.1073/Pnas.0511001103  0.31
2006 Ligon KL, Fancy SP, Franklin RJ, Rowitch DH. Olig gene function in CNS development and disease. Glia. 54: 1-10. PMID 16652341 DOI: 10.1002/Glia.20273  0.314
2005 Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO, Denko NC, Ligon KL, Rowitch DH, Louis DN. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. Journal of Neuropathology and Experimental Neurology. 64: 948-55. PMID 16254489 DOI: 10.1097/01.Jnen.0000186940.14779.90  0.363
2004 Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD, Rowitch DH. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. Journal of Neuropathology and Experimental Neurology. 63: 499-509. PMID 15198128 DOI: 10.1093/Jnen/63.5.499  0.392
2004 Bachoo RM, Kim RS, Ligon KL, Maher EA, Brennan C, Billings N, Chan S, Li C, Rowitch DH, Wong WH, DePinho RA. Molecular diversity of astrocytes with implications for neurological disorders. Proceedings of the National Academy of Sciences of the United States of America. 101: 8384-9. PMID 15155908 DOI: 10.1073/Pnas.0402140101  0.307
2002 Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, Rowitch DH, Louis DN, DePinho RA. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 1: 269-77. PMID 12086863 DOI: 10.1016/S1535-6108(02)00046-6  0.35
1993 Aka K, Bruner JM, Bondy ML, Ligon K, Nishi T, del Giglio A, Moser RP, Levin VA, Saya H. Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. Journal of Neuro-Oncology. 16: 125-33. PMID 7904621 DOI: 10.1007/Bf01324699  0.306
Show low-probability matches.